Ilaris canakinumab regulatory update

The product uses UltiMAb technology from Medarex Inc., which Bristol-Myers Squibb acquired. Regeneron Pharmaceuticals Inc. (NASDAQ: REGN, Tarrytown, N.Y.) is eligible for tiered royalties of 4-15% o...